Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
Ontology highlight
ABSTRACT: BACKGROUND:Hepatitis C virus' (HCV) chronic prevalence among pregnant women in the United States doubled nationally from 2009-2014 (~0.7%), yet many cases remain undiagnosed. Screening pregnant women is not recommended by the Society of Maternal-Fetal Medicine or the Centers for Disease Control and Prevention, despite new American Association For the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidelines recommending screening for this group. We assessed the cost-effectiveness of HCV screening for pregnant women in the United States. METHODS:An HCV natural history Markov model was used to evaluate the cost-effectiveness of universal HCV screening of pregnant women, followed by treatment after pregnancy, compared to background risk-based screening from a he
SUBMITTER: Chaillon A
PROVIDER: S-EPMC7188080 | biostudies-literature | 2019 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA